Statement Of Unitholders' Equity

Oncolys BioPharma Inc. - Filing #7342826

Concept 2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
As at
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
As at
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
2022-01-01 to
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2022-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
As at
2021-12-31
Statement of unitholders' equity
Statement of unitholders' equity
Net assets
14,683,000 JPY
3,623,165,000 JPY
1,474,097,000 JPY
-3,373,199,000 JPY
1,459,413,000 JPY
1,209,590,000 JPY
1,209,590,000 JPY
-142,000 JPY
-3,373,199,000 JPY
-1,434,694,000 JPY
-142,000 JPY
2,159,269,000 JPY
586,425,000 JPY
586,425,000 JPY
2,151,589,000 JPY
3,000,000,000 JPY
-1,434,694,000 JPY
JPY
7,680,000 JPY
7,680,000 JPY
-14,516,735,000 JPY
-113,000 JPY
3,593,992,000 JPY
9,039,516,000 JPY
31,740,000 JPY
-14,516,735,000 JPY
9,031,904,000 JPY
9,063,645,000 JPY
3,586,312,000 JPY
Changes during period
Net changes in items other than shareholders' equity
7,003,000 JPY
7,003,000 JPY
Total changes during period
-692,175,000 JPY
623,165,000 JPY
-1,938,505,000 JPY
7,003,000 JPY
JPY
-685,172,000 JPY
623,165,000 JPY
-1,938,505,000 JPY
623,165,000 JPY
JPY
-31,740,000 JPY
-28,000 JPY
13,367,797,000 JPY
-6,039,516,000 JPY
13,367,797,000 JPY
-8,445,478,000 JPY
-1,148,966,000 JPY
-8,477,219,000 JPY
-1,148,966,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.